S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
Status:
Completed
Trial end date:
2019-03-07
Target enrollment:
Participant gender:
Summary
This randomized phase II trial compares how well two different doses of carfilzomib work when
given with dexamethasone in treating patients with multiple myeloma that has come back after
a period of improvement or has not responded to treatment. Carfilzomib may stop the growth of
cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in
chemotherapy, such as dexamethasone, work in different ways to stop the growth of cancer
cells, either by killing the cells, by stopping them from dividing, or by stopping them from
spreading. Giving carfilzomib together with dexamethasone may kill more cancer cells. It is
not yet known whether a higher or lower dose of carfilzomib works better when given with
dexamethasone.